Mindray's Q3 bottom-line shrinks; top-line management undergoes change
This article was originally published in Clinica
Executive Summary
China's Mindray Medical saw its profits hit by income tax and interest expenses in the third fiscal quarter, resulting in net income declining 4% year-on-year to $35.8 million. Moreover, growth in operating income was also modest (+1% at $39.1 million) due to significantly higher sales expenditure (+16%) and general and administrative costs (+64%). R&D costs also increased by 20%, but as a proportion of revenue, this was kept at a similar level of 9% compared with the same period last year.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.